Abstract
Mycophenolate mofetil (MMF) is an inosine monophosphate dehydrogenase inhibitor, that inhibits the de novo pathway of guanosine nucleotide synthesis, the proliferative responses of T and B lymphocytes as well as antibody production by B-lymphocytes. It is indicated for the prophylaxis of organ rejection after allogeneic cardiac, hepatic and renal transplants . It has recently also been used with good success in patients with lupus nephritis . Based on these actions, MMF appears to be a novel agent for the treatment of systemic sclerosis, especially during early disease where an inflammatory infiltrate preceeds the development of fibrosis. Disease modification early on during the inflammatory stage of systemic sclerosis may lead to an overall decrease in fibrotic complications both in relation to cutaneous and internal organ involvement.
Keywords: Mycophenolate mofetil, mycophenolic acid, fibrosis, systemic sclerosis, scleroderma, treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: The Use of Mycophenolate Mofetil for the Treatment of Systemic Sclerosis
Volume: 8 Issue: 1
Author(s): Max Shenin, Manisha Naik and Chris T. Derk
Affiliation:
Keywords: Mycophenolate mofetil, mycophenolic acid, fibrosis, systemic sclerosis, scleroderma, treatment
Abstract: Mycophenolate mofetil (MMF) is an inosine monophosphate dehydrogenase inhibitor, that inhibits the de novo pathway of guanosine nucleotide synthesis, the proliferative responses of T and B lymphocytes as well as antibody production by B-lymphocytes. It is indicated for the prophylaxis of organ rejection after allogeneic cardiac, hepatic and renal transplants . It has recently also been used with good success in patients with lupus nephritis . Based on these actions, MMF appears to be a novel agent for the treatment of systemic sclerosis, especially during early disease where an inflammatory infiltrate preceeds the development of fibrosis. Disease modification early on during the inflammatory stage of systemic sclerosis may lead to an overall decrease in fibrotic complications both in relation to cutaneous and internal organ involvement.
Export Options
About this article
Cite this article as:
Shenin Max, Naik Manisha and Derk T. Chris, The Use of Mycophenolate Mofetil for the Treatment of Systemic Sclerosis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (1) . https://dx.doi.org/10.2174/187153008783928334
DOI https://dx.doi.org/10.2174/187153008783928334 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Steroids and Vasopressor-Resistant Hypotension in Preterm Infants
Current Pediatric Reviews Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism Daclizumab: A Potential Asthma Therapy?
Recent Patents on Inflammation & Allergy Drug Discovery Treatment of Diabetic Foot Ulcer: An Overview Strategies for Clinical Approach
Current Diabetes Reviews Allergen-Induced Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Current Chemical Biology Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Current Vascular Pharmacology Incidental Extracardiac Findings on Coronary Computed Tomography Angiography: A Pictorial Review of Imaging Findings
Current Medical Imaging Current Updates in the Medical Management of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Mucoadhesive Nanoparticulate System for Oral Drug Delivery: A Review
Current Drug Therapy Inotropic and Vasoactive Drugs in Pediatric ICU
Current Drug Targets Secondary Prevention of Ischemic Stroke
Current Drug Targets The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection
Current Rheumatology Reviews Subject Index to Volume 2
Current Vascular Pharmacology Inflammatory Biomarkers and Therapeutic Targets in Heart Failure
Current Medicinal Chemistry Immunopathological Aspects of Mycoplasma pneumoniae Infection
Current Pediatric Reviews Serelaxin: New Investigational Treatment in Acute Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) Perioperative Management of Patients with Down Syndrome
Current Pediatric Reviews Gene Therapy for the Prevention of Ischemia / Reperfusion Injury in Organ Transplantation
Current Gene Therapy